Trial
NCT03357224
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
Hoffmann-La Roche
Condition
Lymphoma, T-Cell, Cutaneous
Intervention
Atezolizumab
Why stopped
Following an urgent safety measure due to toxicity recruitment has been closed prematurely.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-02-22